ReviewOncogene2002
Telomerase as a therapeutic target for malignant gliomas.
Review in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 77 citations in OpenAlex.
- A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.Journal of neuro-oncology · 2016Trial
- Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.Current medicinal chemistry · 2024Review
- Hyperpolarized δ-[1-Scientific reports · 2023Article
- Construction of a telomere-related gene signature to predict prognosis and immune landscape for glioma.Frontiers in endocrinology · 2023Article
- Transplantation of a Novel Recombinant Adeno-Associated Virus (pAAV-HE1B19K-TE1A) Demonstrates Higher Anti-Tumor Effects in Tumor Cells.Annals of transplantation · 2020Article
- Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.Cytotechnology · 2018Article
- Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?Current treatment options in neurology · 2018Review
- Advances and challenges: dendritic cell vaccination strategies for glioblastoma.Expert review of vaccines · 2017Review
- Vaccination strategies for neuro-oncology.Neuro-oncology · 2015Review
- A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Journal of immunology research · 2014Review
- A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Molecular targeting of neural cancer stem cells: TTAGGG, you're it!Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Targeted therapies for malignant glioma: progress and potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2009Review
- Targeting human telomeric G-quadruplex DNA with oxazole-containing macrocyclic compounds.Biochimie · 2008Article
- Immunotherapy of malignant brain tumors.Immunological reviews · 2008Review
- Defining the mode, energetics and specificity with which a macrocyclic hexaoxazole binds to human telomeric G-quadruplex DNA.Nucleic acids research · 2007Article
- Article
- Genes and pathways downstream of telomerase in melanoma metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.Molecular and cellular biology · 2006Article
- A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.Oncogene · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Telomerase, a ribonucleoprotein enzyme, is considered as a potential target of cancer therapy because of its preferential expression in tumors. In particular, malignant gliomas are one of the best candidates for telomerase-targeted therapy. It is because malignant gliomas are predominantly telomerase-positive, while normal brain tissues do not express telomerase. In theory, there are two telomerase-associated therapeutic approaches for telomerase-positive tumors. One approach is the anti-telomerase cancer therapy to directly inhibit telomerase activity, resulting in apoptotic cell death or growth arrest. Two major components of the telomerase holoenzyme complex, the RNA template (hTER) and catalytic subunit (reverse transcriptase, hTERT) are well considered as therapeutic targets. The other approach is the telomerase-specific cancer therapy by targeting telomerase-expressing tumor cells as a means to directly kill the cells. Strategies using the transfer of therapeutic gene under the hTERT promoter system as well as immunotherapy directed against telomerase-positive cells are generally included. These telomerase-associated therapies are very promising for the treatment of malignant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.